Get started
Author

Qing Zuraw

Observed names: Q Zuraw, Q. C. ZURAW, Q. Zuraw, Qing C Zuraw, Qing C. Zuraw, Zuraw, Q.C.
OpenAlex ID: A5046541588
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
2006 · T. MULLIGAN, M. F. FRICK, et al. · International Journal of Clinical Practice · 763
PDF
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
2017 · Edouard R. Martin, Mark T. Smith, et al. · American Journal of Nephrology · 129
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
2022 · Ronald F van Vollenhoven, Kenneth C Kalunian, et al. · Annals of the Rheumatic Diseases · 89
PDF
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
2021 · Christopher T Ritchlin, Philip S Helliwell, et al. · RMD Open · 69
PDF
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
2025 · Ronald F. van Vollenhoven, Li Wang, et al. · New England Journal of Medicine · 63
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study
2021 · Ronald F. van Vollenhoven, Bevra H. Hahn, et al. · The Journal of Rheumatology · 34
PDF
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce
2023 · Kathryn Connelly, Laura E. Eades, et al. · Nature Reviews Rheumatology · 33
PDF
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
2026 · Jicheng Lv, Lijun Liu, et al. · New England Journal of Medicine · 32
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
2022 · Rebecca Williams-Hall, Pamela Berry, et al. · Lupus Science & Medicine · 15
PDF
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study
2025 · Kathryn Connelly, Rachel Koelmeyer, et al. · Lupus Science & Medicine · 9
PDF
Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study
2025 · Jicheng Lv, Li-Jun Liu, et al. · Journal of the American Society of Nephrology · 7
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE
2023 · Anca D Askanase, Wei Tang, et al. · Lupus Science & Medicine · 7
PDF
Pos1130 Designing of a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Nipocalimab, an Fcrn Inhibitor, in Adults With Primary Sjögren's Syndrome
2023 · J. Hubbard, K. Campbell, et al. · Annals of the Rheumatic Diseases · 2
PDF
A Phase Three, Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG) (P9-9.005)
2026 · George Li, Ali Habib, et al. · Neurology · 1
LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus
2023 · Fang Liu-walsh, Bart van Hartingsveldt, et al. · Lupus Science & Medicine · 1
PDF
Ab0548 Efficacy and Safety of Nipocalimab in Adult Patients With Active Systemic Lupus Erythematosus: Design of a Phase 2 Study
2023 · F. Liu-Walsh, B.V. Hartingsveldt, et al. · Annals of the Rheumatic Diseases · 1
PDF
Ab0982 Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (trm-sle): Results of a Modified Delphi Study
2024 · K. Connelly, R. Koelmeyer, et al. · Annals of the Rheumatic Diseases
LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process
2023 · Kathryn Connelly, Laura Eades, et al. · Lupus Science & Medicine
PDF
611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study
2022 · Fang Liu-Walsh, Bart van Hartingsveldt, et al. · Lupus Science & Medicine
PDF
PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus
2022 · F Liu-Walsh, B Van Hartingsveldt, et al. · Lupus Science & Medicine
PDF
Mp418vadadustat Does Not Prolong Corrected Qt Interval in a Thorough Qtc Study in Healthy Subjects
2017 · Peter McCullough, Matthew Weir, et al. · Nephrology Dialysis Transplantation
PDF
PowerPoint Slides for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
2017 · Martin, E.R., Smith, M.T., et al. · Figshare
Supplementary Material for: Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
2017 · Martin, E.R., Smith, M.T., et al. · Figshare
Works count: 23
Citation count: 1,255
H-index: 9
I10-index: 9
Year
Topic
Type